MSH2 and neoplasm: Finally, we cannot fully exclude that genetic alterations arose during the rederivation process of our Msh2-Lynch mouse line that may have contributed to the loss of intestinal tumor development in the SPF facility, although we found no evidence for this by whole exome sequencing.